Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

Luis G. Paz-Ares, Carlos Gomez-Roca, Jean Pierre Delord, Andres Cervantes, Ben Markman, Jesus Corral, Jean Charles Soria, Yann Bergé, Desamparados Roda, Fiona Russell-Yarde, Simon Hollingsworth, José Baselga, Pablo Umana, Luigi Manenti, Josep Tabernero

Research output: Contribution to journalArticleResearchpeer-review

63 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences